Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

[1]  P. Hopkins,et al.  Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. , 1999, JAMA.

[2]  D. Black,et al.  An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. , 1998, Archives of internal medicine.

[3]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[4]  D. Illingworth,et al.  Rhabdomyolysis after taking atorvastatin with gemfibrozil. , 1998, The American journal of cardiology.

[5]  A. Faggiotto,et al.  Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. , 1997, Atherosclerosis.

[6]  R. Stern,et al.  Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin , 1997, Journal of clinical pharmacology.

[7]  H. Gylling,et al.  1.P.150 Basal non-cholesterol sterols reveal a subgroup of 4S not benefitted by simvastatin-induced decrease of recurrent coronary events , 1997 .

[8]  L. Rallidis,et al.  Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. , 1997, Journal of lipid research.

[9]  J. Kuhlmann,et al.  Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. , 1997, International journal of clinical pharmacology and therapeutics.

[10]  J. Kuhlmann,et al.  Influence of cholestyramine on the pharmacokinetics of cerivastatin. , 1997, International journal of clinical pharmacology and therapeutics.

[11]  E. Stein,et al.  Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia , 1997, Journal of cardiovascular pharmacology and therapeutics.

[12]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[13]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[14]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[15]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[16]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[17]  A. Sedman,et al.  Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase Inhibitor , 1995, Journal of clinical pharmacology.

[18]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[19]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[20]  W. Garnett.  Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[21]  A. Wang,et al.  The interaction of fluvastatin and cyclosporin A in renal transplant patients. , 1995, International journal of clinical pharmacology and therapeutics.

[22]  G Salen,et al.  Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. , 1994, The New England journal of medicine.

[23]  H. Sinzinger,et al.  Treatment of hypercholesterolaemia in children , 1992, The Lancet.

[24]  E. Muls,et al.  Simvastatin use in children , 1992, The Lancet.

[25]  P. Schwandt,et al.  Interaction between fibre and Iovastatin , 1991, The Lancet.

[26]  H. Pan,et al.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. , 1991, British journal of clinical pharmacology.

[27]  D. Illingworth.  Management of hyperlipidemia: goals for the prevention of atherosclerosis. , 1990, Clinical and investigative medicine. Medecine clinique et experimentale.

[28]  T. Gross,et al.  Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. , 1990, JAMA.

[29]  K. K. Larson,et al.  Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. , 1990, Annals of internal medicine.

[30]  J. D. Karkas,et al.  Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. , 1989, Biochemical and biophysical research communications.

[31]  P. Reaven,et al.  Lovastatin, nicotinic acid, and rhabdomyolysis. , 1988, Annals of internal medicine.

[32]  D. Fleming,et al.  More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities. , 1988, The New England journal of medicine.

[33]  Y. Tsujita,et al.  CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. , 1986, Biochimica et biophysica acta.

[34]  C Krogh,et al.  "Compendium of pharmaceuticals and specialties". , 1983, Canadian Medical Association journal.

[35]  Endo Akira,et al.  Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals , 1979 .

[36]  M. Kuroda,et al.  Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.

[37]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[38]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[39]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.

[40]  D. E. Duggan,et al.  Physiological disposition of HMG-CoA-reductase inhibitors. , 1990, Drug metabolism reviews.